ARTICLE | Product Development
BCMA programs begin to find their niches
Safety will likely dictate where different anti-BCMA modalities fit in
December 14, 2019 12:41 AM UTC
Updated on Dec 14, 2019 at 6:44 PM UTC
As CAR Ts, bispecifics and ADCs targeting BCMA battle it out in multiple myeloma, the question is not which modality will win, but whether they can fill different niches in the treatment landscape.
The safety profile of each modality will most likely end up dictating when and where it is used...